Literature DB >> 16284537

Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand.

Richard A Jenkins1, Darawan Thapinta, Patricia A Morgan, Siriluck Wongkamhaeng, Pornchai Sornsathapornkul, Valai Bussaratid, Auchara Sontirat, Punnee Pitisuttithum, Prasert Thongchareoen, Chirasak Khamboonruang, Vinai Suriyanon, Sorachai Nitayaphan, Arthur E Brown.   

Abstract

Behavioral and social issues were investigated in 363 phase I/II preventive HIV-1 vaccine trial volunteers in Thailand. These issues included risk behavior, HIV knowledge, distress, and social consequences of vaccine trial participation. Data were collected at baseline and at 4-, 8-, and 12-month follow-up visits. Volunteers reported relatively low levels of risk behaviors at baseline and at follow-up. Overtly negative reactions from family or friends were reported by 5.9%. No experiences of discrimination in employment, health care, or insurance were reported. Mean levels of distress were low throughout the trial, and HIV-related knowledge was high, although it was common to consider the possibility of HIV transmission through casual contact. Findings add to the evidence that preventive HIV vaccine trials are feasible in Thailand.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284537     DOI: 10.1097/01.qai.0000171725.09812.a5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

2.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

3.  Issues in women's participation in a phase III community HIV vaccine trial in Thailand.

Authors:  Jaranit Kaewkungwal; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirasak Khamboonruang; Prayura Kunasol; Pravan Suntharasamai; Swangjai Pungpak; Sirivan Vanijanonta; Valai Bussaratid; Wirach Maek-A-Nantawat; Jittima Dhitavat; Prasert Thongcharoen; Rungrawee Pawarana; Yupa Sabmee; Mike W Benenson; Patricia Morgan; Robert J O'Connell; Jerome Kim
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

4.  Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.

Authors:  Michele P Andrasik; Fredericka Albertina Sesay; Abby Isaacs; Linda Oseso; Mary Allen
Journal:  J Acquir Immune Defic Syndr       Date:  2020-08-15       Impact factor: 3.731

5.  A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Eric Sandstrom; Fred Mhalu; Asli Kulane
Journal:  BMC Infect Dis       Date:  2011-10-24       Impact factor: 3.090

6.  Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Patricia Munseri; Said Aboud; Muhammad Bakari; Fred Mhalu; Eric Sandstrom
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

7.  Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.

Authors:  April M Young; Daniel S Halgin; Ralph J DiClemente; Claire E Sterk; Jennifer R Havens
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.